Stian Foss

Stian Foss is a Researcher at the Department of Pharmacology, University of Oslo. His work focuses on antibody engineering, immunology, and pharmacology, particularly investigating mechanisms related to FcRn receptors, antibody half-life, and therapeutic applications. He contributes to preclinical studies on antibodies targeting cancer, autoimmune diseases, and viral pathogens.

Research interests include optimizing antibody properties for enhanced efficacy and stability, understanding intracellular immunity via TRIM21 signaling, and developing novel therapeutic strategies using engineered antibodies. His studies often involve collaborations on drug delivery systems and biotechnological advancements.

Recent articles highlight work on Fc-engineered antibodies for cancer therapy, mucosal immunity, and antibody-based treatments for conditions like choroidal neovascularization and pemphigus. His research bridges basic immunology with translational medicine, aiming to improve antibody-based therapies.

Stian Foss is affiliated with the Laboratory of Adaptive Immunity and Homeostasis, where he collaborates on projects involving antibody pharmacokinetics and immune mechanisms. His work has implications for improving drug design, vaccine development, and targeted therapies in oncology and autoimmune disorders.